Clinical Trials on Refractory Liver Carcinoma in China

Total 6970 results

Xinqiao Hospital of Chongqing

Unknown

Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Completed

HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B

Hepatocellular Carcinoma

China
Sun Yat-sen University

Completed

Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-sen University

Unknown

Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication

Hepatocellular Carcinoma

China
Southeast University, China

Unknown

Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis (TACE HCC)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Not yet recruiting

TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria (B-TACE)

Hepatocellular Carcinoma by BCLC Stage

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaborators

Active, not recruiting

Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (REGSIN)

Hepatocellular Carcinoma Non-resectable

China
Xiangya Hospital of Central South University

Active, not recruiting

Thermal Ablation Followed by Immunotherapy for HCC

Hepatocellular Carcinoma Non-resectable

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging

Cirrhosis； Tumor

China
Xiao Xu

Completed

The Dual Impact of Cirrhosis on Transplantation for Hepatocellular Carcinoma：a Two-center Retrospective Cohort Study in China

Hepatocellular Carcinoma | Cirrhosis

China
Chen Xiaoping

Unknown

Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma

Liver Cirrhosis | Hepatocellular Carcinoma

China
Sulai Liu

Recruiting

HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC

Hepatocellular Carcinoma

China
Sun Yat-sen University
Fifth Affiliated Hospital, Sun Yat-Sen University; Ningbo Medical Center Lihuili...

Not yet recruiting

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) (HSBRT2402)

Hepatocellular Carcinoma

China
Meng Chao Hepatobiliary Hospital of Fujian Medical...

Not yet recruiting

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Hepatocellular Carcinoma

China
Wuhan Union Hospital, China

Recruiting

HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

SIRT for Potentially Resectable HCC

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

Hepatocellular Carcinoma

China
Zhejiang University

Recruiting

Prognostic Models for HCC Based on Tumor Micronecrosis

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial

Hepatocellular Carcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image (AI-HCC)

Hepatocellular Carcinoma

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients

Hepatocellular Carcinoma

China
Zhongda Hospital

Recruiting

Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers (CHANCEsub)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shujun Yang
Henan Cancer Hospital

Recruiting

Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC

Hepatocellular Carcinoma

China
Nanfang Hospital of Southern Medical University

Recruiting

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Zhejiang University

Recruiting

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma (CAPT)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial (PLATIC)

Hepatocellular Carcinoma

China
Nanfang Hospital of Southern Medical University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

Hepatocellular Carcinoma

China
Zhongda Hospital

Recruiting

Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma (SAIL)

Hepatocellular Carcinoma

China
Mian XI

Recruiting

Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) (ISBRT01)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC (SOURCE)

Hepatocellular Carcinoma

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shi Ming

Withdrawn

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Hepatocellular Carcinoma

China
Sun Yat-sen University
Innovent Biologics, Inc.

Active, not recruiting

HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC (HAICPD1-HCC)

Hepatocellular Carcinoma

China
Guangxi Medical University

Completed

Simo Decoction and Gum Chewing for Bowel Activity (SD/GC-HCC)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Completed

The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study

Hepatocellular Carcinoma

China
Fuda Cancer Hospital, Guangzhou

Completed

Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder

Hepatic Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma (HCC-009)

Hepatocellular Carcinoma

China
Zhejiang University

Withdrawn

Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation

Hepatocellular Carcinoma

China
RenJi Hospital

Completed

Anti-GPC3 CAR T for Treating Patients With Advanced HCC

Hepatocellular Carcinoma

China
Sun Yat-sen University

Completed

Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC

Hepatocellular Carcinoma

China
Sun Yat-sen University

Completed

Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-sen University

Unknown

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

Hepatocellular Carcinoma

China

3

Subscribe